Crisostomo Paul R, Wang Meijing, Markel Troy A, Lahm Tim, Abarbanell Aaron M, Herrmann Jeremy L, Meldrum Daniel R
Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Shock. 2007 Oct;28(4):375-83. doi: 10.1097/shk.0b013e318058a817.
Heart disease remains the leading cause of death in the industrialized world. Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Cardiac surgery represents the unique situation where preischemia and postischemia treatment modalities exist that may use stem cell paracrine protection. This review (1) recalls the history of stem cells in cardiac disease and the unraveling of its mechanistic basis for protection, (2) outlines the pathways for stem cell-mediated paracrine protection, (3) highlights the signaling factors expressed, (4) explores the potential of using stem cells clinically in cardiac surgery, and (5) summarizes all human stem cell studies in cardiac disease to date.
在工业化国家，心脏病仍然是主要的死亡原因。干细胞疗法是一种治疗受损心脏组织的很有前景的治疗方式。这种心脏保护作用的一种新机制可能包括旁分泌作用。心脏手术呈现出一种独特的情况，即存在缺血前和缺血后治疗方式，这些方式可能利用干细胞旁分泌保护作用。本综述：（1）回顾了干细胞在心脏病治疗中的历史以及其保护作用机制的揭示过程；（2）概述了干细胞介导的旁分泌保护作用的途径；（3）强调了所表达的信号因子；（4）探讨了在心脏手术中临床应用干细胞的潜力；（5）总结了迄今为止所有关于心脏病的人类干细胞研究。
